OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
PAT advances are enabling improved process understanding and control.
Cell-culture optimization may see benefits such as product titer and quality.
Upstream processing automation advances with connected systems and improved data analytics.
March 02, 2021
Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.
February 02, 2021
Connected, integrated bioprocessing enterprises with greater data analytics capabilities are coming.
January 02, 2021
Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.
December 02, 2020
Establishing an automated inline dilution system can potentially ease bottlenecking delays resulting from higher upstream yields.
November 02, 2020
PAT advances are enabling improved process understanding, process control, and error prevention.
October 02, 2020
An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.
Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.
September 03, 2020
This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.
August 02, 2020
Process modeling offers an opportunity to troubleshoot for and anticipate difficult aspects of a bioprocess.
July 02, 2020
Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.
June 01, 2020
Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.
May 01, 2020
Synthetic biology has advanced the scope and scale with which biologically derived therapeutics can be developed.
April 03, 2020
New bioreactor designs, coupled with better media, process intensification and analytics, continue to improve upstream bioprocessing.
March 09, 2020
The new BIOSTAT STR Generation 3 with BIOBRAIN bioproduction platform offers process intensification with automated feed and bleed and integrated cell retention functionality.
March 02, 2020
Better understanding and control of cell behavior is yielding benefits, upstream and beyond.
The future of raw material sourcing for mAb production may lay in the sustainability of the source and the added benefits of newer technologies.
February 05, 2020
By establishing effective management of data and knowledge, it will be possible to employ advances, such as artificial intelligence and synthetic biology, to their full potential in upstream bioprocessing.
February 01, 2020
The production of viral vectors for use in gene therapy benefits from being able to use similar cell-culture processes as mAbs, but it faces limitations under current cell-culture technologies.
January 15, 2020
Horizon Discovery Group and Mammoth Biosciences have signed a collaboration and license agreement aimed at the development of the next generation of engineered Chinese hamster ovary (CHO) cell lines to improve biotherapeutics production.
January 01, 2020
Industry experts debate the pros and cons of “going bigger” than the 2000-L industry norm in a single vessel.